These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21808135)

  • 1. Fas receptor (CD95) & Fas ligand (CD178) expression in patients with tobacco-related intraoral squamous cell carcinoma.
    Das SN; Khare P; Singh MK; Sharma SC
    Indian J Med Res; 2011 Jul; 134(1):54-60. PubMed ID: 21808135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of cyclin D1 expression with aggressive DNA pattern in patients with tobacco-related intraoral squamous cell carcinoma.
    Das SN; Khare P; Singh MK; Sharma SC
    Indian J Med Res; 2011 Apr; 133(4):381-6. PubMed ID: 21537090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio.
    Chien MH; Chang WM; Lee WJ; Chang YC; Lai TC; Chan DV; Sharma R; Lin YF; Hsiao M
    Mol Cancer Ther; 2017 Jun; 16(6):1102-1113. PubMed ID: 28292939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FAS/FASL expression profile as a prognostic marker in squamous cell carcinoma of the oral cavity.
    de Carvalho-Neto PB; dos Santos M; de Carvalho MB; Mercante AM; dos Santos VP; Severino P; Tajara EH; Louro ID; da Silva-Conforti AM
    PLoS One; 2013; 8(7):e69024. PubMed ID: 23894399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of FasL expression in oral squamous cell cancer.
    Fang L; Sun L; Hu FF; Chen QE
    Asian Pac J Cancer Prev; 2013; 14(1):281-5. PubMed ID: 23534738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of fas (CD95) ligand is correlated with IL-10 and granulocyte colony-stimulating factor expression in oral and oropharyngeal squamous cell carcinoma.
    Fujieda S; Sunaga H; Tsuzuki H; Fan GK; Ito T; Sugimoto C; Saito H
    Cancer Lett; 2000 Dec; 161(1):73-81. PubMed ID: 11078915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of ADAM10, Fas, FasL and Soluble FasL in Patients with Oral Squamous Cell Carcinoma (OSCC) and their Association with Clinical-Pathological Parameters.
    Zepeda-Nuño JS; Guerrero-Velázquez C; Del Toro-Arreola S; Vega-Magaña N; Ángeles-Sánchez J; Haramati J; Pereira-Suárez AL; Bueno-Topete MR
    Pathol Oncol Res; 2017 Apr; 23(2):345-353. PubMed ID: 27628319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of DNA pattern of metastatic lymph node with disease free survival in patients with intraoral squamous cell carcinoma.
    Das SN; Khare P; Patil A; Pandey RM; Singh MK; Shukla NK
    Indian J Med Res; 2005 Sep; 122(3):216-23. PubMed ID: 16251778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of Fas ligand and down-regulation of Fas expression in oral carcinogenesis.
    Chen Q; Samaranayake LP; Zhen X; Luo G; Nie M; Li B
    Oral Oncol; 1999 Nov; 35(6):548-53. PubMed ID: 10705088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Fas/FasL in patients with oral lichen planus.
    Hadzi-Mihailovic M; Raybaud H; Monteil R; Jankovic L
    J BUON; 2009; 14(3):487-93. PubMed ID: 19810143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications.
    Korkolopoulou P; Saetta AA; Levidou G; Gigelou F; Lazaris A; Thymara I; Scliri M; Bousboukea K; Michalopoulos NV; Apostolikas N; Konstantinidou A; Tzivras M; Patsouris E
    Histopathology; 2007 Aug; 51(2):150-6. PubMed ID: 17559541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression and significance of Fas and FasL protein in squamous cell carcinoma of larynx].
    Shi L; Li G; Zhu C
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Dec; 16(12):661-2. PubMed ID: 12669436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.
    Shibakita M; Tachibana M; Dhar DK; Kotoh T; Kinugasa S; Kubota H; Masunaga R; Nagasue N
    Clin Cancer Res; 1999 Sep; 5(9):2464-9. PubMed ID: 10499620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of Fas (APO-1/CD95) ligand in human colorectal cancer.
    Sheehan KM; O'Donovan DG; Fitzmaurice G; O'Grady A; O'Donoghue DP; Sheahan K; Byrne MF; Conroy RM; Kay EW; Murray FE
    Eur J Gastroenterol Hepatol; 2003 Apr; 15(4):375-80. PubMed ID: 12655257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of Fas and FasL protein expression in gastric carcinoma and local lymph node tissues.
    Li Q; Peng J; Li XH; Liu T; Liang QC; Zhang GY
    World J Gastroenterol; 2010 Mar; 16(10):1274-8. PubMed ID: 20222173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FAS ligand expression in inflammatory infiltrate lymphoid cells as a prognostic marker in oral squamous cell carcinoma.
    Peterle GT; Santos M; Mendes SO; Carvalho-Neto PB; Maia LL; Stur E; Agostini LP; Silva CV; Trivilin LO; Nunes FD; Carvalho MB; Tajara EH; Louro ID; Silva-Conforti AM
    Genet Mol Res; 2015 Sep; 14(3):11145-53. PubMed ID: 26400345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma.
    Satchell AC; Barnetson RS; Halliday GM
    Br J Dermatol; 2004 Jul; 151(1):42-9. PubMed ID: 15270871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of Fas receptor and negative correlation of Fas ligand with differentiation and apoptosis in oral squamous cell carcinoma.
    Loro LL; Vintermyr OK; Johannessen AC; Liavaag PG; Jonsson R
    J Oral Pathol Med; 1999 Feb; 28(2):82-7. PubMed ID: 9950255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations.
    Korkolopoulou P; Goudopoulou A; Voutsinas G; Thomas-Tsagli E; Kapralos P; Patsouris E; Saetta AA
    Urology; 2004 Jun; 63(6):1198-204. PubMed ID: 15183989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The distribution and intracellular location of Fas and Fas Ligand following gastric carcinogenesis: Fas Ligand expressing gastric carcinoma cells can inhibit local immune response.
    Liu H; Ubukata H; Tabuchi T; Nakachi T; Nagata H; Shimazaki J; Motohashi G; Konishi S; Nishimura M; Satani T; Hong J; Nakada I; Saniabadi AR; Tabuchi T
    Mol Cell Biochem; 2009 Nov; 331(1-2):181-6. PubMed ID: 19458913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.